Bibliography
- Buckingham SC, Campbell SL, Haas BR, Glutamate release by primary brain tumors induces epileptic activity. Nat Med 2011;17(10):1269-74
- Ye ZC, Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res 1999;59:4383-91
- Takano T, Lin JH, Arcuino G, Glutamate release promotes growth of malignant gliomas. Nat Med 2001;7:1010-15
- Savaskan NE, Heckel A, Hahnen E, Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat Med 2008;14:629-32
- Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010;97:11-23
- de Groot J, Sontheimer H. Glutamate and the biology of gliomas. Glia 2011;59(8):1181-9
- Sato H, Tamba M, Ishii T, Bannai S. Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 1999;274:11455-8
- Lo M, Wang YZ, Gout PW. The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008;215:593-602
- Powis G, Briehl M, Oblong J. Redox signalling and the control of cell growth and death. Pharmacol Ther 1995;68:149-73
- Bridges RJ, Natale NR, Patel SA. System x(c) (-) cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. Br J Pharmacol 2012;165:20-34
- Patel SA, Rajale T, O'Brien E, Isoxazole analogues bind the system xc- transporter: structure-activity relationship and pharmacophore model. Bioorg Med Chem 2010;18:202-13
- Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 2001;15:1633-40
- Shaffer PL, Goehring A, Shankaranarayanan A, Gouaux E. Structure and mechanism of a Na+-independent amino acid transporter. Science 2009;325:1010-14
- Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem 2009;110:182-93
- Chung WJ, Lyons SA, Nelson GM, Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci 2005;25:7101-10
- Zheng W, Winter SM, Mayersohn M, Toxicokinetics of sulfasalazine (salicylazosulfapyridine) and its metabolites in B6C3F1 mice. Drug Metab Dispos 1993;21:1091-7
- Azadkhan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol 1982;13:523-8
- Robe PA, Martin DH, Nguyen-Khac MT, Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer 2009;9:372
- Shukla K, Thomas AG, Ferraris DV, Inhibition of xc transporter-mediated cystine uptake by sulfasalazine analogs. Bioorg Med Chem Lett 2011;21:6184-7